3 news items
Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers
DAWN
18 Jun 24
and adult medicines in areas of unmet need with equal urgency," said Dr. Samuel Blackman, co-founder and head of research and development at Day One. "We
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
DAWN
6 May 24
.R&D Expenses: Research and development expenses were $40.2 million for the first quarter of 2024 compared to $27.8 million
Day One's OJEMDAâ„¢ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
DAWN
23 Apr 24
Blackman, co-founder and head of research and development at Day One. "As a pediatric neuro-oncologist, the approval of OJEMDA is a dream realized
- Prev
- 1
- Next